Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Research and development expenses and reimbursements due

Such reimbursements were recognized under the collaboration arrangement with R-Pharm during the quarter ended March 31, 2015. Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the three months ended March 31, 2015 and 2014, is presented as follows:

	Three Months Ended March 31,
	2015		2014
Research and development expense, gross	$	4,412	$	1,320
Less: Reimbursement of research and development expense	194		—
Research and development expense, net of reimbursements	$	4,218	$	1,320